Latest news with #Zoetis'
Business Wire
5 days ago
- Business
- Business Wire
Zoetis Releases 2024 Sustainability Progress Update
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis published its 2024 Sustainability Progress Update 'Advancing Sustainability in Animal Health for a Better Future' to highlight the company's continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis' fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and the Planet – that strengthen its business by creating long-term value, enhancing stakeholder trust, and supporting sustainable growth. 'Zoetis contributes to a healthier future for communities, animals and the planet thanks to our colleagues who demonstrate their commitment to the Driven to Care strategy and are empowered to advance our company's purpose,' said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, and Chief Sustainability Officer at Zoetis and President of the Zoetis Foundation. 'By embedding our sustainability strategy across our business, and through purposeful partnerships with our customers and other stakeholders, our actions address challenges at the intersection of people, animals and the environment.' Highlights of the company's progress in 2024 include: Communities – Care and Collaboration 20,404 hours of community-based volunteer time reported by colleagues, which represents 102% of the company's stated goal and a 23% increase from hours reported in 2023. Zoetis provides paid time off for colleagues to volunteer and support animals, their caregivers, and local communities. The Zoetis Foundation disbursed $11.3 million in grants in 2024 ($26.2 million since 2021), supporting education, well-being, and livelihoods for veterinarians and farmers as well as humanitarian aid and a matching gifts program. The grantmaking in 2024 included $3.5 million in funding that will provide nearly 500 veterinary student scholarships. $8.9 million invested in communities through Zoetis Inc. corporate giving; efforts included vet care access to approximately 322,000 pet owners in need and providing care to approximately 428,000 animals affected by disasters. 86% colleague engagement rate driven by a culture anchored in Core Beliefs; the company's focus on colleagues includes talent development programs, mentorship and coaching, and comprehensive benefits to foster an inclusive workplace where every colleague can thrive. Animals – Innovation in Animal Health Launched a strategic partnership with Danone, leveraging Zoetis' genetics expertise to advance the dairy industry's approach to breeding cattle for sustainability. Also, began a research collaboration with AgNext to close data gaps and meet the evolving sustainability needs of the cattle industry. Introduced solutions for Highly Pathogenic Avian Influenza (HPAI) including existing vaccines used to help protect California Condors in the U.S. and trialed on five species of endangered birds in New Zealand. Treated 16.7 million cows and 354.9 million chickens in Sub-Saharan Africa, exceeding goals, through the company's African Livestock Productivity and Health Advancement (A.L.P.H.A. Plus) initiative. Planet – The Drive to Protect our Planet Continued progress toward carbon neutrality in the company's own operations, reducing total Scope 1 and 2 emissions by 26.7% from 2023. This reduction was primarily driven by increased renewable energy credits procured through a virtual power purchase agreement. 80.6% of the company's global electricity is from renewable sources. The company's locations covered by renewable electricity include 15 manufacturing sites, its R&D headquarters in Kalamazoo, Michigan, and its international headquarters office in Dublin, Ireland. Installed an 800kW solar array at the Rutherford manufacturing site in Australia – making it Zoetis' eighth location to generate a portion of its power through on-site solar energy. Implemented new sustainable packaging solutions and reduced waste through recycled paper packaging for a cattle vaccine in Europe and replaced single use with reusable pallets and transitioned from air to sea freight in Spain. For more detailed disclosures on the company's sustainability programs, practices and policies, please download Zoetis' 2024 Sustainability Progress Update or visit Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care aspirations, and report annually. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit DISCLOSURE NOTICES Forward-Looking Statements: This press release and the 2024 Sustainability Progress Update (including the 2024 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned 'Forward-Looking Statements and Factors That May Affect Future Results' and 'Item 1A. Risk Factors,' in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at or on request from Zoetis. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. See the footnotes within our 2024 Sustainability Progress Update for more details regarding all calculations.
Yahoo
23-05-2025
- Business
- Yahoo
2 Dividend Stocks to Buy With $500 and Hold Forever
Zoetis is a leading animal health company with a deep lineup and significant long-term tailwinds. Abbott Labs has a diversified portfolio of medical devices and several attractive growth avenues. Both healthcare stocks have impeccable dividend track records and bright futures still ahead. 10 stocks we like better than Zoetis › Broader equities have been volatile this year, but that's par for the course. The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest. However, times like these might help remind us that some corporations are more resilient than others. Among the most resilient are longtime dividend payers with excellent underlying businesses and strong outlooks. That description fits Zoetis (NYSE: ZTS) and Abbott Laboratories (NYSE: ABT), two giants in the healthcare sector. For those with $500 to spare (not being saved for emergencies) and in the market for income stocks to park in their portfolios, here's why these two companies are outstanding candidates to put that money into now. Zoetis is a leading animal health company. The company's portfolio of products is deep and diversified. It markets medicines for companion animals, livestock, fish, poultry, and more. Zoetis has over 300 product lines and about 15 that generate over $100 million in annual revenue. Despite its usually strong performance, Zoetis has encountered some issues in the past year. The company's guidance for its fiscal 2025 was weak, or at least so the market thought. Furthermore, Zoetis will face increased competition for one of its growth drivers. The company's Apoquel, which helps relieve allergic itch in dogs, has been a top performer, but one of Zoetis' rivals, Elanco Animal Health, launched an alternative last year. While competition has been, and will continue to be, one of Zoetis' threats, the animal health specialist has been successful despite that. It routinely grows its revenue at a faster rate than the industry average. It is the leader, or one of the market leaders, across most categories and regions where it operates. The company also has important long-term growth drivers. Zoetis' companion animal segment generates the most revenue and is the most promising. Younger generations (millennials and Gen Z) have fewer kids than previous generations but are increasingly humanizing pets. Some of the spending which, for older folks, would have gone into caring for children will be redirected toward cats and dogs due to this dynamic. That should benefit Zoetis, which continues to develop and market newer and better pet care products. That's just one long-term tailwind. Here's another. A growing world population will lead to an increased demand for animal protein. To provide that in spades, we need to care for livestock, something else Zoetis specializes in. The company might encounter issues in the short run due to marketwide troubles and mounting competition, but Zoetis' long-term prospects look attractive thanks to its impressive track record in the industry and its existing lineup of products. Lastly, Zoetis is a terrific dividend stock, even with a mediocre forward yield of 1.2% -- the S&P 500's average is 1.3%. Zoetis has increased its payouts by 502% in the past decade while still boasting a conservative cash payout ratio of 34.2%. The stock should consistently deliver more dividend growth and solid returns to investors holding on to it for good. Abbott Laboratories is best known for its work in the medical device market. Sure enough, this segment is home to its most attractive sources of revenue and biggest growth drivers, but one of the company's strengths is its diversification. Abbott is also a leader in nutrition, boasts a solid diagnostic segment, and markets various pharmaceutical products. Abbott Laboratories has succeeded in keeping its business afloat even when significant problems in one segment or another arise, thanks to its reliance on multiple sources of revenue. That's why it routinely generates consistent revenue and earnings. Meanwhile, the company's prospects look strong. One of the company's key growth drivers is its FreeStyle Libre franchise, a family of continuous glucose monitoring (CGM) systems. The healthcare leader has to contend with stiff competition from DexCom in this area, but despite this long-standing challenge, the FreeStyle Libre has become the most successful medical device ever in terms of dollar sales -- and there is still ample room for growth, considering that the worldwide CGM diabetes market remains underpenetrated. Elsewhere, several other product lines and segments should see increased demand over the long run due to an aging worldwide population. Consider Abbott's MitraClip, a minimally invasive option to treat a serious heart problem called mitral valve regurgitation. This issue is more common among people aged 65 and older. That's why demand for the MitraClip (or other products like it that Abbott manufactures) will grow as people aged 65 and up make up a larger percentage of the population. It might not make a massive difference for just one of these products, but higher demand across the range of the company's portfolio will meaningfully affect its results. Turning to Abbott's income profile, the company has raised its payouts for 53 consecutive years, making it a Dividend King. The stock might only offer a yield of 1.8%, but its cash payout ratio looks reasonable at 60.4%. Abbott will encounter some issues. It is facing lawsuits over its infant formula products for premature babies allegedly causing fatal illnesses, among others. It will also have to deal with a competitive landscape and, potentially, the continuing threat of tariffs that could increase its costs and squeeze its bottom line. However, Abbott's strong presence in the healthcare industry, solid underlying business, and innovative capabilities should allow it to continue performing well over the long run, despite the headwinds. It's an excellent buy-and-hold forever stock for income seekers. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $644,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $807,814!* Now, it's worth noting Stock Advisor's total average return is 962% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Zoetis. The Motley Fool recommends DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. 2 Dividend Stocks to Buy With $500 and Hold Forever was originally published by The Motley Fool
Time Magazine
08-05-2025
- Health
- Time Magazine
Kristin Peck
Kristin Peck wants to change how you think about treating and preventing animal disease. Not only is their welfare an ethical obligation, it's also inseparable from the environment, economics, and our own health. 'Animals can help humans live longer,' says Peck, who is CEO of the global animal health company Zoetis. She helped launch Zoetis in 2012 because animal health 'spoke to me personally,' after growing up with a family raising horses, dogs, cats, and birds. Her passion for protecting animals has translated into major achievements, including 25 million doses of Zoetis' innovative arthritis medication given to dogs, starting in 2021 through the present. Zoetis has developed a new vaccine to protect chickens from the currently circulating Avian Influenza H5N1 virus that has infected 168 million birds in the U.S. since early 2022, decimating the poultry industry. In Feb. 2025, the U.S. government issued a license for the vaccine, though it has yet to be distributed for use in poultry farms. This followed the government's use of Zoetis' H5N1 vaccine in 2023 to protect endangered California condors. Zoetis' work pushes beyond U.S. borders: Zoetis distributes vaccines for eight animal species in more than 100 countries. In 2024, its H5N3 vaccine saved endangered birds in New Zealand. Peck's favorite part of the job is traveling to rural Africa, Asia, and Latin America to see how Zoetis' vaccinations are protecting livestock in low-income locales. 'Keeping animals healthy makes such a difference for community health,' she says.
Yahoo
27-03-2025
- Business
- Yahoo
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Shares in animal pharmaceutical company Zoetis (NYSE: ZTS) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations. That said, a fair number of variables could influence Zoetis' revenue in 2025, and focusing just on revenue guidance might not be the best way to think about the stock. One major alternative consideration could end up providing an upside or downside to expectations. Management and investors know that competitors have new products entering the market in 2025. Indeed, on the earnings call, CFO Wetteny Joseph said the operational organic revenue growth forecast of 6% to 8% "included a range of assumptions for new market entrants and conditions across our business." However, it's unclear how successful the new entrants will be, or whether they will affect Zoetis more or less than management expects in its guidance. A second alternative consideration could provide an upside. According to Joseph, management's guidance "does not include products that have not yet been approved." However, during the JPMorgan Healthcare Conference in January, CEO Kristin Peck showed a chart indicating three expected pharmaceutical product approvals over the next 12 months, five over the next 12 months to 36 months, and seven over the next 36 months to 60 months. As such, there's potential for some contribution from products potentially approved in 2025. Indeed, Peck told conferencegoers: "We're also super excited that we're going to have at least one approval each year for [the] next several years that will drive significant growth for the company." The potential approvals do provide some upside to 2025 guidance. Thinking longer-term, they are what will drive growth at Zoetis. Management believes pharmaceutical products approved for chronic kidney disease (dogs) and oncology (dogs) could open up markets worth up to $5.7 billion. That's something to think about. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $697,245!* Now, it's worth noting Stock Advisor's total average return is 845% — a market-crushing outperformance compared to 165% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of March 24, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase and Zoetis. The Motley Fool has a disclosure policy. Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy. was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now
It is a beautiful thing when you find a feel-good stock that offers market-beating potential. A perfect example of this combination today is animal healthcare specialist Zoetis (NYSE: ZTS). Whether helping our furry friends at home, keeping livestock healthy, or doing its part to battle the bird flu outbreak that has sent egg prices sky high, Zoetis is easy to root for these days. And it has been a market-beating proposition since its 2013 initial public offering, more than quintupling investors' returns over that time. However, following a 36% drop in share price, the stock is available at a rare discount. Here are the five main reasons that have me doubling up on my position in this magnificent S&P 500 dividend stock. Zoetis creates medicines, vaccines, genetic tests, diagnostics, and precision animal health products for companion animals and livestock alike. The company is well-diversified across the animal healthcare industry. Some notable statistics: It focuses on eight core species: dogs, cats, cows, chickens, pigs, horses, fish, and sheep. It has 15 blockbuster products earning $100 million or more annually. It has more than 300 product lines. Over 2,000 new products or innovations were created in the last decade. Two-thirds of sales are generated from companion animals and one-third from livestock. 55% of its sales come from the United States and 45% internationally. 90% of its sales come from products that are No. 1 or No. 2 in their respective market share. The company has been growing faster than the overall animal healthcare industry every year since 2014 thanks to its penchant for continuous innovation. Management believes the veterinary healthcare category will grow by 5% annually through 2032 with the megatrend in the humanization of pets, giving the company a rosy outlook. Zoetis' newest blockbusters are its osteoarthritis (OA) pain treatments for dogs and cats: Librela and Solensia. These monoclonal antibodies offer improved efficacy compared to traditional non-steroidal anti-inflammatory drugs and have quickly proved to be popular among pet owners. The two OA pain treatments increased sales by 80% in 2024 (and 20% in the fourth quarter against a tougher comparable) and are already the company's fourth-largest franchise. With roughly 40% of cats and dogs getting OA in their lifetimes, Librela and Solensia will likely remain popular options among pet owners who are increasingly willing to spend more to care for their furry friends. Cats and dogs are living longer than ever, and the prevalence of OA will rise as these pets age, making Zoetis' newest blockbuster treatments even more valuable with time. Librela is currently treating only 10% of dogs with OA, so plenty of room for growth remains. Zoetis has shown an ability to recreate itself through product innovations and new treatments, and its profitability has steadily gone from good to outstanding. Its net profit margin has more than tripled since 2012, and return on invested capital (ROIC) has grown to 21%, which ranks in the top quintile of the S&P 500. Stocks with high and rising ROICs have historically outperformed their lower-ranked peers since they generate outsize profits compared to their debt and equity. This profitability creates a flywheel effect, as Zoetis can reinvest in its operations through more research and development or mergers and acquisitions, while also allowing it to reward shareholders handsomely. Thanks to its ballooning profitability, Zoetis has grown its dividend by 22% annually over the last decade. At the same time, however, the company has also reduced its total shares outstanding by 1% annually since 2014, creating my favorite "X factor" chart. These stock buybacks help juice Zoetis' earnings per share (EPS) figures since the denominator of the EPS equation (total shares) keeps shrinking over time. The shares' 36% drop in price means these stock repurchases are even more valuable because management can eliminate shares at a discount. Furthermore, even though the company's dividend yield sits at all-time highs, it requires only 32% of net income, leaving plenty of room for future increases. Currently, Zoetis trades at a price-to-earnings ratio (P/E) of 29 and a dividend yield of 1.2%. Both of these metrics are at their most attractive levels in the company's history, making this a once-in-a-decade opportunity. Its discounted price combined with a long track record of steady growth, rising profitability, and returning cash to shareholders make Zoetis my favorite S&P 500 dividend stock to double up on right now. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $823,858!* Now, it's worth noting Stock Advisor's total average return is 917% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of February 21, 2025 Josh Kohn-Lindquist has positions in Zoetis. The Motley Fool has positions in and recommends Zoetis. The Motley Fool has a disclosure policy. A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now was originally published by The Motley Fool Sign in to access your portfolio
